Evacetrapib Fails to Reduce Major Adverse Cardiovascular Events

Despite lowering low-density lipoprotein (LDL), known as “bad” cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or “good” cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to new research. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail